Signed, Sealed, Delivered: Evolving Treatment Options for the Management of Perianal Fistula in Crohn’s Disease
Roundtable #2
***Pre-Assessment***

Before you view the webinar, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit. Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

There is no fee to participate in this activity.
1.Where are you in your career?(Required.)
2.The addition of which of the following to an anti-TNF agent is associated with a higher rate of CPF healing vs the anti-TNF agent alone?
3.A 25-year-old male with a recent diagnosis of CD presents with extreme perianal pain. A pelvic MRI is performed, leading to a diagnosis of CPF and abscess. Drainage of abscess and An examination under anesthesia is performed, during which a seton is placed in an intersphincteric fistula. The patient asks what to expect regarding his future course of therapy. 

Which of the following is an appropriate response?
4.A 42-year-old female with refractory CPF asks about the possibility of receiving mesenchymal stem cell (MSC) therapy on a clinical trial. What do you tell the patient is an important education point regarding MSCs?
5.According to the 2022 proposed new Expert Consensus (published in The Lancet Gastroenterology & Hepatology, linked here), refractory CPF despite ostomy requiring proctectomy is considered which class?
6.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity).
*Please note that we will not forward or sell your contact information.*
(Required.)
Privacy & Cookie Notice